Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
OtherRecruiting Location: Australia
Does tiotropium bromide lead to bronchodilation in cystic fibrosis? , protocol number ACTRN12605000728639
Does tiotropium bromide lead to bronchodilation in cystic fibrosis?
Age:
Not Specified
Mutation(s):
Not specified
FEV1% Predicted:
Number of Visits:
Length of Participation:
Anti-InfectiveEnrolling Location: Australia
Evaluation of CF patient perception of symptom improvement following inhaled antibiotic treatment. , protocol number ACTRN12605000602628
Diagnosis of CF and chronic PA infection (defined as cultures positive for PA for > 6 months, including most recent culture). Have adequate understanding of English to give informed consent and follow study procedures. Patient must have completed their most recent course of TOBI or aerosolized tobramycin solution or any other aerosolized antibiotic at least 28 days prior to study entry. Parent/guardian of children 6 to 13 years old must agree to complete the CFQ-R and Global Rating of Change Questionnaires. Patient's physician must have decided to prescribe a 28 day course of TOBI for treatment of clinical symptoms (increased cough, increased sputum production/chest congestion, decreased exercise tolerance, or decreased appetite).
6 years - no stated upper limit
OtherEnrolling Location: Australia
Effect of a targetted exercise program versus current exercise practice on function, activity and participation of young people with cystic fibrosis: a randomised, controlled trial , protocol number ACTRN12607000612415
Exercise is a vital component of the physiotherapy management for young people with cystic fibrosis (CF). The overall aim of this research is to strengthen knowledge about best practice exercise programs for this population. This study compares effects of two exercise programs (the current exercise practice versus a novel targeted exercise program). Ultimately, it is expected that with improved exercise programs, young people with CF may have improved body structure and function, and activity and participation levels, leading to enhanced quality of life.
18-70 years
40% predicted or above
BehavioralEnrolling Location: Australia
Engaging and re-connecting 'at-risk' children with chronic respiratory illness. , protocol number ACTRN12607000515493
Children with chronic illness sometimes feel disconnected and lonely. In this study we will evaluate the use of a psycho-social intervention program for 'at-risk' children (ie. child with chronic illness, low socio-economic groups) to improve their sense of well-being, adherence to therapies and health outcomes.
10-15 years
BehavioralNot yet recruiting Location: Australia
Stretching in cystic fibrosis: does it improve the quality of life and measures of kung function. , protocol number ACTRN12608000484347
Stretching in cystic fibrosis: does it improve the quality of life and measures of kung function.
>40% or above
A comparative assessment of the clinical impact , protocol number ACTRN12607000349448
This study is designed to provide vitally needed information on the clinical implications of being infected by a clonal strain of P. aeruginosa and the risk factors for the acquisition of a clonal strain. This new information will provide a rational basis for the need for changes to infection control policies and better outcome predictors for patients infected with clonal strains of P. aeruginosa.
2-75 years
Restore CFTR FunctionCompleted with results Location: USA & Australia
Phase 3 study of inacaftor in babies who have a CFTR gating mutation , protocol number NCT02725567 VX15-770-124
This two-part, open label study is taking place at multiple care centers across the US. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.
0 Months to 24 Months
One Copy F508del or No Copies F508del
No FEV1 Limit
8
24 weeks
Restore CFTR FunctionCompleted with results Location: Multiple US sites & Australia
Phase 2 study of VX-440 combination drug in people with cystic fibrosis. , protocol number NCT02951182 VX15-440-101
This study is taking place at multiple care centres accross the US. It will look at the safety and effectiveness of the drug VX-440 in combination with ivacaftor and/or tezacaftor (VX-661)
18 years and older
homozygous or hetrozygous F508del
40 - 90%
11
57
Restore CFTR FunctionEnrolling Location: Australia
Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1) , protocol number NCT02707562
A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation
>18 years
G551D
Pre- or post-bronchodilator FEV1 ≥ 40% of predicted normal
Restore CFTR FunctionCompleted with results Location: Australia
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation , protocol number NCT02514473 VX14-809-109
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
6-11 years
homozygous for the F508del CFTR mutation
ppFEV1 of ≥70 p